首页> 美国卫生研究院文献>NPJ Digital Medicine >Developing and adopting safe and effective digital biomarkers to improve patient outcomes
【2h】

Developing and adopting safe and effective digital biomarkers to improve patient outcomes

机译:开发和采用安全有效的数字生物标记物以改善患者预后

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Biomarkers are physiologic, pathologic, or anatomic characteristics that are objectively measured and evaluated as an indicator of normal biologic processes, pathologic processes, or biological responses to therapeutic interventions. Recent advances in the development of mobile digitally connected technologies have led to the emergence of a new class of biomarkers measured across multiple layers of hardware and software. Quantified in ones and zeros, these “digital” biomarkers can support continuous measurements outside the physical confines of the clinical environment. The modular software–hardware combination of these products has created new opportunities for patient care and biomedical research, enabling remote monitoring and decentralized clinical trial designs. However, a systematic approach to assessing the quality and utility of digital biomarkers to ensure an appropriate balance between their safety and effectiveness is needed. This paper outlines key considerations for the development and evaluation of digital biomarkers, examining their role in clinical research and routine patient care.
机译:生物标志物是生理,病理或解剖学特征,可以对其进行客观地测量和评估,以作为正常生物学过程,病理过程或对治疗干预措施的生物学反应的指标。移动数字连接技术发展的最新进展导致出现了一类新的生物标记物,可跨多个硬件和软件层进行测量。这些“数字”生物标记物以1和0进行量化,可以支持在临床环境物理范围之外的连续测量。这些产品的模块化软硬件组合为患者护理和生物医学研究创造了新的机遇,从而实现了远程监控和分散的临床试验设计。但是,需要一种系统的方法来评估数字生物标记的质量和实用性,以确保其安全性和有效性之间的适当平衡。本文概述了开发和评估数字生物标记物的主要注意事项,并检查了它们在临床研究和常规患者护理中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号